ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
205,000
-10,500 (-4.87%)
Jan 9, 2026, 12:00 PM KST
547.71%
Market Cap11.88T
Revenue (ttm)88.44B
Net Income (ttm)-28.65B
Shares Out55.13M
EPS (ttm)-575.68
PE Ration/a
Forward PE1,073.45
Dividendn/a
Ex-Dividend Daten/a
Volume494,521
Average Volume998,954
Open212,500
Previous Close215,500
Day's Range203,500 - 213,500
52-Week Range29,400 - 224,000
Beta0.51
RSI65.42
Earnings DateFeb 6, 2026

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.